CPP 2nd Dose Grant

This post is the second in a series on increasing adolescent immunizations. For a case study on how one health system increased their overall adolescent vaccination rates, see our previous post.

The CPP 2nd Dose Program provides an opportunity to examine your practice’s 2nd dose immunization rates for vaccines that require more than one dose to complete the series, access resources to help implement a strategy in your office to raise those rates, and share successful strategies with other CPP members. Applicable vaccines include meningococcal ACWY, HPV, adult pneumococcal and/or adult hepatitis B (Heplisav-B only). 

The tables below show immunization rates for these vaccines for the most recent year available from the CDC:

National, Regional, State, and Selected Local Area Vaccination Coverage Among Adolescents Aged 13-17 Years—United States, 2017

Vaccine Coverage Among Adults in the United States, National Health Interview Survey, 2016

Participants in CPP’s 2nd Dose Program have already seen successes. Over 77% of member participants reported that their 2nd dose immunization rates were lower than they expected when they pulled the initial data from their EMR. After implementing an intervention in their practice to help improve these rates, participants saw a rise in their HPV and MCV4 completion rates by an average of 29% and 41%, respectively! 

Some best practices that were shared by the group include:

Check out the CPP 2nd Dose Program website for updated resources and details on how your practice can participate in this $1,000 grant opportunity!

How a Large Health System Increased Adolescent Vaccination Rates

This post is the first in a series on adolescent vaccination.

When Sanford Health, a rural not-for-profit health system based in the Dakotas, Minnesota, and Iowa, took a look at their adolescent vaccination rates, they were shocked by what they found. Baseline rates for the completion of the HPV series ranged from 15%-29% in their clinics, and rates for completion of the Meningococcal series ranged from just 8%-38%. Sanford decided to make system-wide changes to improve their adolescent vaccination rates.

Sanford began by creating an immunization strategy department lead by the Immunization Strategy Manager. A cross-department team gathered to form an enterprise immunization committee and craft a plan. The initial stage focused on increasing administration of the HPV vaccine at a test group of seven clinics. The strategy consisted of three parts:

  • Providers were given their immunization rates as well as those of their colleagues. This put accurate data into the providers’ hands and engendered a sense of competition between staff.
  • Sanford emphasized a “no missed vaccination opportunity” culture, encouraging providers to assess immunization status for every patient at every encounter.
  • The system sent reminder and recall letters to parents of adolescents.

Over the two year test period, HPV completion rates increased by an average of 15%, and zero-dose rates decreased an average of 22%. Armed with this data, Sanford made plans to expand the program. The organization added standing orders for most vaccines, enabling RNs, LPNs, and MAs to administer immunizations. These orders eliminated more missed opportunities and empowered staff to own their immunization rates.

Sanford, with the help of the Immunization Action Coalition and Sanofi Pasteur, also created a curriculum to train people to become immunization champions. The VAX Champ program created immunization champions content experts for each clinic. The program also trained its students to examine current vaccination rates and create plans to improve them. These interventions saw first and second dose rates for MenACWY climb steadily. In some clinics, second dose rates more than doubled.

Sanford Health’s efforts helped to not only increase adolescent vaccination rates but also advanced their mission to improve patient health. These steps can be applied to healthcare systems or offices of any size. Sanford’s success shows that with dedication and a solid plan adolescent immunization rates can improve.

Next in this series is a guide to CPP’s 2nd Dose Program that rewards members for improving second dose rates of several immunizations, including those that Sanford highlighted. For more information, visit our website.

2019-2020 Flu Vaccine Timeline

Recently, Sanofi Pasteur provided an update for the distribution of influenza vaccine for the 2019-2020 flu season.  Due to late-emerging A/H3N2 viruses that delayed the strain selection for the upcoming flu season, it is anticipated that the delivery of Sanofi Pasteur influenza vaccines will be approximately 3-4 weeks behind the shipping commitments previously communicated.  Sanofi Pasteur fully expects to manufacture and deliver every dose reserved by their customers, beginning with partial shipments to all customers in late-August or September, with all shipments completed by the end of November.

Each year, the World Health Organization (WHO) and U.S. Food and Drug Administration (FDA), with help from epidemiologists around the world, select the virus strains to be included in influenza vaccines for the upcoming season.  This year, due to late-emerging A/H3N2 viruses that circulated globally, the WHO and FDA decided to delay selection of the A/H3N2 strain by one month.  This allowed health authorities to collect additional data to help improve the match of the vaccine strain to the A/H3N2 strain anticipated to circulate during the 2019-2020 season.

Sanofi Pasteur fully supports this decision by health authorities to collect additional data and make a more informed selection.

If you have any questions, please feel free to contact the CPP office at 614-722-2145 or your Sanofi Pasteur representative.

Sanofi Pasteur’s Adacel (Tdap) Vaccine FDA Approved for Repeat Vaccination after 8 Years

The Food and Drug Administration recently approved the Adacel (Tdap) vaccine to be administered as soon as 8 years after a previous dose. Adacel, manufactured by Sanofi Pasteur, provides immunity to tetanus, diphtheria, and pertussis. The vaccine is approved for patients ages 10-64, and is available in a syringe made without natural rubber latex.

The current CDC recommendations for Tdap are as follows:

  • Adolescents should receive a single dose, preferably at age 11 or 12
  • All pregnant women should receive a single dose during pregnancy, preferably between weeks 27 and 36. By receiving this vaccine, pregnant mothers pass antibodies to their babies, reducing the risk of whooping cough.
  • Adults should receive a single dose of Tdap followed by a booster Td every 10 years.

FDA approval was based on clinical data from a study that showed no significant differences in adverse events when adults received Adacel versus Td 8-12 years after a previous dose of Adacel.  The approval of Adacel administration every 8 years provides more flexibility for physicians in both vaccine purchasing decisions and immunizations scheduling. Sanofi has provided study results to the CDC for consideration in future recommendations.

For more information or to purchase Adacel or any other immunization, visit our website or send us an email

AAP Releases “Immunization Information Technology Guide” for pediatricians

At CPP’s recent Vaccine Management Summit, 2D barcoding stood out as a topic of interest among attendees. CPP members will find a new AAP guide helpful as they continue to learn about this technology.

The AAP recently released a guide for pediatricians with information on two key information technology topics: immunization information systems and two dimensional barcoding. In addition, the AAP provides a detailed website for both topics that summarizes the information found in the new guide and provides relevant links.

Immunization Information Systems, also known as vaccine or immunization registries, are confidential computerized systems that capture vaccination data across the lifespan within a certain geographical area. The use of these systems can reduce healthcare costs and improve patient care. The benefits to pediatric practices of using these systems include minimizing duplicate vaccine administration, aiding in recalling patients overdue for vaccinations, reminding patients of upcoming immunizations, and identifying vulnerable patients during a disease outbreak.

Two Dimensional Barcode Scanning Technology can be used with the majority of pediatric vaccines. Recent studies show that the use of 2D scanning increase accuracy in vaccine documentation and reduces documentation time by an average of 21 seconds. 2D barcode scanning improves practice efficiency, increases vaccine inventory accuracy, and assists in proper billing. In addition, the technology benefits patients by improving safety and documentation, reducing errors, and identifying expired vaccines before they are administered to patients. The AAP’s 2D barcoding resources include practice uses, choosing a scanner, and getting the scanner to “work.”   

For practices not yet ready to implement 2D barcoding, CPP has other resources to help manage your vaccine inventory including a Vaccine Inventory Reconciliation Sheet. These resources can be found on our website.

CPP Vaccine Summit a Success

The inaugural CPP Buying Group – Vaccine Management Summit on May 2 was a great success. More than 100 vaccine professionals from across the state attended the conference to gain knowledge from industry leaders. Dr. Kristen Feemster, Director of Research for the Vaccine Education Center at Children’s Hospital of Philadelphia, kicked off the summit with a comprehensive review of vaccines on the horizon.

The first round of breakout sessions focused on Central Ohio Primary Care’s efforts to improve pediatric and adult vaccination rates, a presentation about maximizing savings when purchasing vaccines, and a discussion on vaccine documentation and coding.

CPP staff hard at work at the registration table.

The second group of breakout sessions included a panel discussion between representatives of Pediatric Associates and the Ohio AAP on creating a culture of vaccination, a presentation by Mount Carmel Health on inventory management and 2D barcoding, and information from the Ohio Department of Health concerning vaccine storage guidelines and updates.

Attendee feedback was overwhelmingly positive.  CPP staff and planning committee members are already working to make the next summit even better.

AAP Flu Vaccine Update: No preference for injected vaccine over nasal spray

On March 14, 2019, the AAP issued a press release stating it does not recommend the inactivated flu vaccine, which is injected, over the quadrivalent live attenuated influenza vaccine, which is given via nasal spray to healthy patients ages 2 through 49. This recommendation for the 2019-2020 flu season reverses a prior preference for the injectable vaccine.

CPP members can take advantage of our partnership with AstraZeneca and receive a discount on doses of FluMist®. Please contact the CPP office at cpp@nationwidechildrens.org or 614-722-2145 to obtain a declaration form that needs to be completed to access this discount. Members can pre-book their FluMist doses by contacting an authorized distributor (McKesson or FFF Enterprises) by June 30, 2019.

Vaccine Management Summit – Registration Deadline Approaching

Please join us on May 2, 2019 for the first ever Vaccine Management Summit hosted by CPP at the Renaissance Hotel Westerville-Polaris.  This half-day conference will feature keynote speaker, Dr. Kristen Feemster, who will provide insight into vaccines on the horizon and the potential impact to your practice.

The remainder of the time will be spent engaging in lively user discussions through breakout sessions:

  • Storage Guidelines & Updates
  • Inventory Management & 2D Barcoding
  • Linking Quality, Performance, and Incentives
  • Coding, Documentation & Other Operational Issues
  • Financial Analysis & Minimizing Cost
  • Creating a Culture of Vaccination

Come ready to share your experiences and learn what is working well for others!

Registration is open to all members of your vaccine management team.  We look forward to seeing you!

Expanded Indication for 0.5mL Fluzone® Quadrivalent

The 0.5mL dose of Sanofi Pasteur’s Fluzone Quadrivalent vaccine has been newly approved to be used in children 6 months of age and older. This new option offers health care providers the simplicity of using the same 0.5mL dose for all eligible children when immunizing against the flu.  Fluzone Quadrivalent 0.25mL dose will still be available to order for children ages 6-35 months for the 2019-2020 season.

If you have already confirmed your 2019-2020 Sanofi Pasteur influenza vaccine reservation, you have the ability to adjust these quantities based on this new approval.

Contact your representative from Sanofi Pasteur or click here for more information.

New CPP Partnership with AstraZeneca!

CPP is pleased to announce a new partnership with AstraZeneca that provides our members a discount opportunity on doses of FluMist®, an intranasal influenza vaccine, for the upcoming 2019-2020 flu season.  Members who opt into this contract will receive a discount off the list price of doses ordered through an authorized distributor throughout the entire 2019-2020 flu season.  Authorized distributors of FluMist currently include McKesson Medical-Surgical Inc. and FFF Enterprises Inc.

To access this discount, please contact the CPP office at cpp@nationwidechildrens.org or 614-722-2145 to obtain pricing details, updated terms and conditions as well as a declaration form.  If you participated in the FluMist discount in prior flu seasons under CPP-MedImmune contract, we will still need an updated declaration form to show your acceptance of the new agreement under AstraZeneca.

Members who are interested in pre-booking FluMist doses should place their reservations with an authorized distributor prior to March 31, 2019.

We hope this will be of interest to your practice as we are always trying to find ways to provide more value to our members!